Ampio Pharmaceuticals (FRA:APH0) ROE %: -185.68% (As of Dec. 2023)


FRA:APH0 Ampio Pharmaceuticals Inc FRA:APH0
35 GF Score
Price €3.62
View Full Analysis

What is Ampio Pharmaceuticals ROE %?

Ampio Pharmaceuticals FRA:APH0 35 ROE % is -185.68% as of Dec. 2023. GuruFocus rates FRA:APH0 with a GF Score™ of 35/100.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ampio Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was €-7.54 Mil. Ampio Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was €4.06 Mil. Therefore, Ampio Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -185.68%.

The historical rank and industry rank for Ampio Pharmaceuticals's ROE % or its related term are showing as below:

FRA:APH0's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.18
* Ranked among companies with meaningful ROE % only.

Ampio Pharmaceuticals  (FRA:APH0) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7.536/4.0585
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.536 / 0)*(0 / 6.212)*(6.212 / 4.0585)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.5306
=ROA %*Equity Multiplier
=N/A %*1.5306
=-185.68 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7.536/4.0585
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-7.536 / -7.536) * (-7.536 / -8.124) * (-8.124 / 0) * (0 / 6.212) * (6.212 / 4.0585)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9276 * N/A % * 0 * 1.5306
=-185.68 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Ampio Pharmaceuticals ROE % Related Terms


Ampio Pharmaceuticals ROE % Historical Data

* Premium members only.

The historical data trend for Ampio Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ampio Pharmaceuticals ROE % Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -235.88 -129.39 -78.42 -87.44 -111.41

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.76 -160.76 -75.45 -83.09 -185.68

FRA:APH0 vs EFTR, VBIVQ, VRTX: ROE % Comparison

For the Biotechnology subindustry, Ampio Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ampio Pharmaceuticals ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's ROE % falls into.


FRA:APH0
35GF Score
Ampio Pharmaceuticals Inc FRA:APH0
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ampio Pharmaceuticals ROE % Calculation

Ampio Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-7.916/( (11.129+3.081)/ 2 )
=-7.916/7.105
=-111.41 %

Ampio Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-7.536/( (5.036+3.081)/ 2 )
=-7.536/4.0585
=-185.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -185.68% mean?
Ampio Pharmaceuticals (FRA:APH0) has a ROE % of -185.68% as of Dec. 2023. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ampio Pharmaceuticals and its competitors.
Is Ampio Pharmaceuticals' ROE % too high?
Ampio Pharmaceuticals' current ROE % is -185.68%. Overall, Ampio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Ampio Pharmaceuticals' ROE % compare to EFTR and VBIVQ?
Ampio Pharmaceuticals' ROE % of -185.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ampio Pharmaceuticals and its competitors. Ampio Pharmaceuticals's current ROE % is -185.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ampio Pharmaceuticals stock overvalued right now?
Ampio Pharmaceuticals (FRA:APH0) has a current ROE % of -185.68%. The current ROE % is -185.68%. Ampio Pharmaceuticals' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ampio Pharmaceuticals (FRA:APH0), the current ROE % is -185.68% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ampio Pharmaceuticals Business Description

Address 9800 Mount Pyramid Court, Suite 400, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee (OAK) as part of its OA-201 development program (OA-201 program or OA-201).
35GF Score

Get the complete analysis for FRA:APH0

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.62
Price